MedTrace Logo

Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)

NCT00842127 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2009-02-12

No results posted yet for this study

Summary

The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyperactivity disorder(ADHD).

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

OROS-methylphenidate (Concerta)

dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks

Sponsors & Collaborators

  • Hallym University Medical Center

    collaborator OTHER

  • Bundang CHA Hospital

    lead OTHER

Principal Investigators

  • Ki-Hwan Yook, MD,PhD · Department of psychiatry CHA university college of medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842127 on ClinicalTrials.gov